CSE Bulletin: Delist - Better Plant Sciences Inc.

The common shares of Better Plant Sciences Inc. will be delisted from the CSE at market close today, May 27, 2025.

Better Plant Sciences is currently suspended. See Bulletin 2024-0121.

_________________________________

Les actions ordinaires de Better Plant Sciences Inc. seront radiées du CSE à la clôture du marché aujourd'hui, le May 27, 2025.

Better Plant Sciences est actuellement suspendu. Voir le Bulletin 2024-0121.

Date : Market Close/Clôture du marchés le 27 mai/May 2025
Symbol(s)/Symbole(s) : PLNT.X

 

If you have any questions or require further information, please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com.

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com.

News Provided by Newsfile via QuoteMedia

PLNT.X:CC
The Conversation (0)
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News